West Nile virus vaccines

@article{Hall2004WestNV,
  title={West Nile virus vaccines},
  author={Roy A. Hall and Alexander A. Khromykh},
  journal={Expert Opinion on Biological Therapy},
  year={2004},
  volume={4},
  pages={1295 - 1305}
}
West Nile virus (WNV) is a mosquito-borne flavivirus that is emerging as a global pathogen. In the last decade, virulent strains of the virus have been associated with significant outbreaks of human and animal disease in Europe, the Middle East and North America. Efforts to develop human and veterinary vaccines have taken both traditional and novel approaches. A formalin-inactivated whole virus vaccine has been approved for use in horses. DNA vaccines coding for the structural WNV proteins have… Expand
Vaccine Development Against West Nile Virus
TLDR
It is indicated that the virus will remain a serious public health problem for the foreseeable future and the population most at risk of severe and fatal WNV infection, and hence the likely recipients of vaccination, are the elderly and immunosuppressed. Expand
A Hydrogen Peroxide-Inactivated Virus Vaccine Elicits Humoral and Cellular Immunity and Protects against Lethal West Nile Virus Infection in Aged Mice
TLDR
The studies suggest that the H2O2-inactivated WNV-KUNV vaccine is safe and immunogenic and may be suitable for protection against WNV infection in vulnerable populations. Expand
A Review of Vaccine Approaches for West Nile Virus
TLDR
The West Nile virus (WNC) first appeared in North America in 1999 and the establishment and recent spread of lineage II WNV virus strains into Western Europe and the presence of neurovirulent and neuroinvasive strains among them is a cause of major concern. Expand
Complex Adenovirus-Mediated Expression of West Nile Virus C, PreM, E, and NS1 Proteins Induces both Humoral and Cellular Immune Responses
TLDR
Results from this study show that multiple antigens synthesized de novo from a CAdVax vector are capable of inducing both humoral and cellular immune responses against WNV and that a multiantigen approach may provide broad protection against multiple genetic variants of WNV. Expand
Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.
TLDR
These studies confirm the attenuation of WN/DEN4Delta30 for non-human primates, including dengue-immune monkeys, and demonstrate both a highly restricted replication in the brain of mice inoculated IC and an absence of infectivity for birds, findings that indicate this vaccine should be safe for both the recipient and the environment. Expand
Nucleic Acid-Based Infectious and Pseudo-Infectious Flavivirus Vaccines
TLDR
SRIP-producing DNA was shown to be highly effective in mice and horses and provides an easier to manufacture and thermally stable alternative to other vaccine candidates currently being developed. Expand
West Nile Virus Infection.
TLDR
WNV has reached an endemic pattern in North America, but the future epidemiologic pattern is uncertain; protection from mosquito bites and other preventative measures are critical. Expand
New developments in flavivirus vaccines with special attention to yellow fever
TLDR
Traditional approaches to flavivirus vaccines are still employed, while recent advancements in biotechnology produced new approaches to vaccine design, such as recombinant live virus, subunit and DNA vaccines. Expand
Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus.
TLDR
The mechanisms by which the immune system limits dissemination of West Nile virus infection are discussed, and important roles for both the innate and the adaptive immune responses in controlling WNV infection are suggested. Expand
Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus.
TLDR
An attenuated WNV strain developed by the ablation of the glycosylation sites in the envelope (E) and non-structural 1 (NS1) proteins is described, which showed modest reduction in multiplication kinetics in cell culture and small plaque phenotype compared to the parental strain. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 97 REFERENCES
West Nile virus vaccine.
TLDR
The aim of this brief review is to describe the features of West Nile encephalitis, a newly introduced infectious disease affecting humans, horses and wildlife in the United States; the rationale for rapidDevelopment of vaccines; and approaches to the development of vaccines against the disease. Expand
Prospects for Development of a Vaccine against the West Nile Virus
  • T. Monath
  • Biology, Medicine
  • Annals of the New York Academy of Sciences
  • 2001
TLDR
A novel technology platform for live, attenuated recombinant vaccines (ChimeriVax™) represents a promising approach for rapid development of a West Nile vaccine. Expand
Current Status of Flavivirus Vaccines
  • A. Barrett
  • Biology, Medicine
  • Annals of the New York Academy of Sciences
  • 2001
TLDR
The “Chimerivax” platform has been used to construct chimeric Japanese encephalitis and dengue viruses that are in different phases of development and similar strategies are being used by other laboratories. Expand
A live attenuated West Nile virus strain as a potential veterinary vaccine.
TLDR
The attenuated variants preserve the ability to replicate in mice and geese and to induce a protective immune response and were successfully used as a live vaccine to protect geese against a wild-type virulent WNV field isolate that closely resembles the WNV isolated during the 1999 New York epidemic. Expand
West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays
TLDR
This recombinant antigen has great potential to become the antigen of choice and will facilitate the standardization of reagents and implementation of WN virus surveillance in the United States and elsewhere. Expand
Growth characteristics of the veterinary vaccine candidate ChimeriVax™‐West Nile (WN) virus in Aedes and Culex mosquitoes
TLDR
The results suggest that the natural mosquito vectors of WN and YF viruses, which may incidentally take a bloodmeal from a vaccinated host, will not become infected with ChimeriVax™‐WN(vet) virus. Expand
The molecular biology of West Nile Virus: a new invader of the western hemisphere.
  • M. Brinton
  • Biology, Medicine
  • Annual review of microbiology
  • 2002
TLDR
A large body of data on the molecular biology of WNV and other flaviviruses has already been obtained, and aspects of virion structure, the viral replication cycle, viral protein function, genome structure, conserved viral elements, host factors, virus-host interactions, and vaccines are discussed in this review. Expand
Flavivirus DNA vaccines: current status and potential.
TLDR
Evidence is provided that the virus-like particles composed of premembrane/membrane and envelope proteins are essential for eliciting immune responses similar to those induced by live, attenuated virus vaccines, as demonstrated by a single intramuscular immunization of DNA vaccine of Japanese encephalitis and West Nile viruses. Expand
Flavivirus DNA Vaccines
TLDR
Results provided evidence that the virus‐like particles composed of premembrane/membrane and envelope proteins are essential for eliciting immune responses similar to those induced by live, attenuated virus vaccines. Expand
Equine vaccine for West Nile virus.
TLDR
Results indicate that the killed WNV vaccine developed by Fort Dodge Animal Health is safe and efficacious. Expand
...
1
2
3
4
5
...